Palisade Bio, Inc. Common Stock PALI

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

PALI hizo una agrupación de acciones (split inverso) de 1:15 el 8 de abril de 2024: cada 15 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 28 sept

  Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

  Palisade Bio announced that its lead program PALI-2108, an oral PDE4 inhibitor prodrug, will be featured in four presentations at UEG Week 2026 in Barcelona. The presentations will showcase Phase 1b findings in fibrostenotic Crohn's disease, early clinical activity in ulcerative colitis, favorable safety and tolerability, gut-targeted exposure, and a biomarker to predict treatment response. PALI-2108 is advancing into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.

  

• GlobeNewswire Inc. 23 sept

  Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

  Palisade Bio announced Health Canada's clearance of its Clinical Trial Application for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance expands the study's geographic reach alongside prior U.S. regulatory approval. The company expects to begin patient dosing in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.

  

• GlobeNewswire Inc. 3 sept

  Palisade Bio to Participate in Upcoming Investor Conferences

  Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced that management will participate in three major healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference (Sept 8-10), Morgan Stanley Global Healthcare Conference (Sept 14-16), and H.C. Wainwright Global Investment Conference (Sept 14-16). The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug, into Phase 2 clinical trials for inflammatory bowel disease treatment.